Alexion's cash cow receives label expansion; Matthew Dallas tapped to CFO post at Zealand Pharma
→ Back in June, Alexion‘s cash cow Soliris scored an additional FDA OK for the treatment of neuromyelitis optica spectrum disorder (NMOSD) — and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
